All News

The FDA granted fast track designation to the ADC SOT106 for soft tissue sarcoma, with a first-in-human trial planned this year.

Results from the phase 3 VERIFY trial led to the approval of rusfertide in polycythemia vera.

Matteo S. Carlino, MD, PhD, FRACP, explains how the individualized neoantigen therapy V940 is designed and delivered in melanoma.

Matthew Matasar, MD, detailed how retrieval-augmented generation tools are already informing real tumor board decisions in hematologic malignancies.

Paxalisib produced a 100% clinical benefit rate and an 83% objective response rate in patients with metastatic triple-negative breast cancer.

ASCO has issued a critical drug supply warning as some practices report just weeks of ifosfamide inventory remaining, with no direct substitute available.

Enrollment for a phase 1 trial evaluating ADI-212, an armored allogeneic gamma delta 1 CAR T cell therapy, in metastatic CRPC is planned for Q4 2026.

Neoadjuvant botensilimab plus balstilimab produced major pathologic responses in 41% of pMMR and 100% of dMMR colorectal tumors in the phase 2 NEST trial.

Surbhi Sidana, MD, discusses the first CELMoD and first MRD-based approval, iberdomide, in relapsed/refractory multiple myeloma.

New CNS metastasis data link gabapentin to fewer brain mets, spotlight trial barriers, and show promise for intrathecal therapy and osimertinib.

Matthew Matasar, MD, discussed his role leading the division of blood disorders at Rutgers Cancer Institute amid a transformative era in immunotherapy.

In the final analysis of the phase 3 MAIA trial, daratumumab-based treatment yielded a median overall survival of 90.3 months in transplant-ineligible NDMM.

According to Nicholas Hornstein, MD, PhD, daraxonrasib is “the first ever effective systemic therapy for pancreas cancer that is not a chemotherapy.”

Final phase 1/1b data for soquelitinib in T-cell lymphoma showed a 37.5% ORR and a 28.1-month median OS in patients who received 1 to 3 prior lines of therapy.

The regulatory submission to expand the gedatolisib label to HR+/HER2-, PIK3CA-mutant advanced breast cancer is based on positive VIKTORIA-1 trial data.

Josef Vymazal, MD, DSc, discusses a prospective study comparing delayed single- and double-dose gadopiclenol MRI for detecting small brain metastases.

Surbhi Sidana, MD, discusses how CELMoDs like iberdomide could complement CAR T and bispecific antibody therapy.

The FRα-directed ADC rinatabart sesutecan showed disease control regardless of biomarker status and is now under investigation in the phase 3 RAINFOL-03 trial.

Ayal Aizer, MD, MHS, describes an adaptive planning trial using synthetic CT to improve same-day treatment accuracy for anatomically unstable brain metastases.

Oncology experts discussed the wide-ranging benefits of exercise in oncology care, including enhanced treatment efficacy, minimal AEs, and minimal expenses.

The FDA has approved daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma based on RASolute 302 trial data.

In a real-world setting, venetoclax plus a hypomethylating agent produced a median overall survival of 13.0 months in newly diagnosed acute myeloid leukemia.

The availability of iberdomide as an easy-to-give, orally available drug “is tremendous” for patients with multiple myeloma, according to Surbhi Sidana, MD.

Experts discussed the rapidly expanding radiopharmaceutical paradigm and how to integrate such technology into real-world oncology practice.

Lizza Hendriks, MD, PhD, discussed why every patient with CNS metastases deserves a multidisciplinary team discussion.

The FDA granted fast track designation to the pan-RAS molecular glue ERAS-0015 for metastatic pancreatic adenocarcinoma.

Starting lenvatinib at 14 mg instead of the trial’s 20-mg dose helps patients remain on therapy, according to Susana Campos, MD, MPH.

In a real-world setting, enfortumab vedotin plus pembrolizumab produced a 50.2% ORR among patients with metastatic/locally advanced urothelial carcinoma.

The FDA has approved zanidatamab plus chemotherapy for the first-line treatment of HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma.

Japan’s MHLW approved sevabertinib for HER2-mutant advanced or recurrent NSCLC across all lines of therapy based on phase 1/2 SOHO-01 data.